New & Notable
AstraZeneca's GLP-1 pill succeeds in two mid-stage trials
AstraZeneca is moving its GLP-1 pill, elecoglipron, into phase 3 development after revealing positive results from two mid-stage studies, with final readouts slated for June.
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
Following escalating legal threats from federal regulators regarding plans to sell an unapproved form of Novo Nordisk’s Wegovy pill, Hims said it “decided to stop offering access” to the treatment
— BioPharma Dive
Nearly half of TrumpRx drugs have generic options available
Of the 43 drugs listed on TrumpRx, 20 have generic versions available in the United States. And most others can be purchased through previously existing discount programs.
The most valuable up-and-coming GLP-1s
Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.
— PharmaVoicePfizer dips on new data for obesity drug acquired in $10B deal
— BioPharma DiveNovo combination obesity shot meets goal in diabetes trial
— BioPharma DiveAstraZeneca leans into obesity, striking deal with China’s CSPC
— BioPharma DiveHealthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Fractyl Health's Revita reduces post-GLP-1 weight regain by ~70%
Fractyl Health's outpatient endoscopic procedure, Revita, reduces post-GLP-1 weight regain by ~70% after 6 months, midpoint cohort data shows.
-
Roche's top obesity drug outperforms Wegovy in phase 2 trial
Roche's leading obesity drug achieved up to 22.5% weight loss in a mid-stage trial, reinforcing its bid to challenge market leaders Eli Lilly and Novo Nordisk.
-
Novo expands diabetes partnership with Aspect Biosystems
Novo Nordisk and Canadian bioprinting company Aspect Biosystems build on their 2023 deal to develop cell-based treatments for diabetes.
-
Trust concerns hinder agentic AI adoption, orchestration
Despite significant investment, most pharmaceutical and life sciences companies are struggling to bring agentic AI into production, a new report says.
-
Nvidia partners with Lilly to launch $1B AI drug discovery lab
Nvidia and Eli Lilly team up to invest $1 billion in a new AI lab to speed up drug discovery using Nvidia's BioNeMo platform and its next-gen Vera Rubin architecture.
-
Novo's Wegovy pill hits the market with a $149 cash-pay price
Novo Nordisk has launched oral Wegovy in the U.S., with cash-pay pricing starting at $149 per month for the lowest doses and ranging up to $299 for higher doses.
Features
-
5 emerging AI/ML trends in clinical research
Emerging AI and machine learning tools are reshaping clinical research as trial sponsors continue to grapple with rising costs, lengthy timelines and low success rates.
-
5 trends defining the next wave of life sciences M&A
As the market rebounds, five key trends are shaping the next wave of mergers and acquisitions in the life sciences industry.
-
GLP-1 drugs primed for FDA approval in 2026
With Pharma titans Eli Lilly and Novo Nordisk continuing to duke it out for control of the GLP-1 market, both are seeking FDA approval for new drugs this year.
-
Blurring the line between GLP-1 compounders, counterfeiters
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.